Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial

Type 1 diabetes is a common autoimmune disease due to destruction of pancreatic β cells, resulting in lifelong need for insulin. Evidence suggest that maintaining residual β-cell function can improve glucose control and reduce risk of hypoglycaemia and vascular complications. Non-clinical, preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcovecchio, M. Loredana, Wicker, Linda S., Dunger, David B., Dutton, Susan J., Kopijasz, Sylwia, Scudder, Claire, Todd, John A., Johnson, Paul R. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194454/
https://www.ncbi.nlm.nih.gov/pubmed/32399500
http://dx.doi.org/10.12688/wellcomeopenres.15697.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194454/
https://www.ncbi.nlm.nih.gov/pubmed/32399500
http://dx.doi.org/10.12688/wellcomeopenres.15697.1

Ejemplares similares